A Real-World Study of Precision Treatment for Advanced Cholangiocarcinoma Based on Molecular Subtyping

NCT07164703 | Not Yet Recruiting

• 1 other identifier: FJPH-CCA-PT-2025
• Study Type: observational
• Target: 55
• Locations: 1 country
• Sites: 1

Brief Summary

This is a multi-center, real-world study aiming to evaluate the efficacy and safety of precision treatment for advanced cholangiocarcinoma (CCA) with different molecular subtypes.

Conditions

Advanced Cholangiocarcinoma (Part 1)

Outcome Measures

Primary Outcomes (1)

• Objective response rate, ORR

  The Objective response rate (ORR) was defined as the complete response (CR) rate or the partial response (PR) rate according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.

  Four weeks after the initiation of medication

Secondary Outcomes (5)

• Overall survival, OS

  From date of enrollment until the date of death from any cause, assessed up to 48 months

• Progression-free survival, PFS

  From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 48 months

• Disease control rate, DCR

  Four weeks after the initiation of medication

• Treatment-related adverse events, TRAEs treatment-related adverse events

  From the initiation of medication, with recordings made whenever an adverse reaction occurs, assessed up to 48 months

• Conversion Resection Rate, CRR

  Four weeks after the initiation of medication until the day before surgery

Study Arms (1)

Precision Treatment Based on Molecular Subtyping (or Gene Mutations)

Drug: Targeted drugs or immunotherapies for cholangiocarcinoma based on targetable gene mutations.

Interventions

Targeted drugs or immunotherapies for cholangiocarcinoma based on targetable gene mutations. DRUG

Targeted drugs or immunotherapies for cholangiocarcinoma based on targetable gene mutations.

Precision Treatment Based on Molecular Subtyping (or Gene Mutations)

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

The study population will include male and female adults aged 18 to 75 years. Participants must have histologically confirmed, unresectable advanced biliary tract carcinoma, which encompasses intrahepatic or extrahepatic cholangiocarcinoma (CCA) and gallbladder cancer.A key criterion for inclusion is the presence of a documented targetable gene mutation, such as FGFR2 fusion/rearrangement, IDH-1 or IDH-2 mutations, ERBB2 (HER2) amplification/overexpression, BRAF V600E mutation, or others.Eligible patients are required to have at least one measurable lesion according to RECIST 1.1 criteria and a good performance status, indicated by an Eastern Cooperative Oncology Group (ECOG) score of 0 or 1. Furthermore, participants must have a life expectancy of more than 3 months and adequate organ function, including Child-Pugh class A or B liver function and specified levels of hematologic and renal function.

You may qualify if:

• Age ≥ 18 and ≤ 75 years.
• Histologically confirmed, unresectable advanced biliary tract carcinoma, including cholangiocarcinoma (intrahepatic or extrahepatic) and gallbladder cancer (diagnosed according to the 2025 Chinese Society of Clinical Oncology (CSCO) Guidelines for Biliary Tract Malignancies and confirmed by a multidisciplinary team). Must have a documented targetable gene mutation, including but not limited to: Fibroblast Growth Factor Receptor 2 (FGFR2) fusion/rearrangement, Isocitrate Dehydrogenase (NADP(+)) 1 (IDH-1) and Isocitrate Dehydrogenase (NADP(+)) 2 (IDH-2) mutations, Erb-B2 Receptor Tyrosine Kinase 2 (ERBB2/HER2) amplification and/or overexpression, B-Raf Proto-Oncogene, Serine/Threonine Kinase (BRAF) V600E mutation, Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) mutation, Neurotrophic Tyrosine Receptor Kinase (NTRK) fusion, Rearranged during Transfection (RET) fusion, Ring Finger Protein 43 (RNF43) mutation, MET Proto-Oncogene, Receptor Tyrosine Kinase (MET) amplification, Epidermal Growth Factor Receptor (EGFR) mutation, Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA) mutation, BRCA1 DNA Repair Associated (BRCA1)/BRCA2 DNA Repair Associated (BRCA2) mutation, Partner and Localizer of BRCA2 (PALB2) mutation, Vascular Endothelial Growth Factor Receptor (VEGFR) mutation, deficient Mismatch Repair (dMMR)/Microsatellite Instability-High (MSI-H), or Neuregulin 1 (NRG1) mutation.
• At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 (measurable lesion defined as longest diameter ≥10 mm on Computed Tomography (CT)/Magnetic Resonance Imaging (MRI) scan).
• Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
• Child-Pugh class A or B liver function. For patients with obstructive jaundice, total bilirubin must be ≤ 50 µmol/L. Biliary drainage is recommended if total bilirubin is \> 50 µmol/L.
• Adequate hematologic function: Absolute Neutrophil Count (ANC) ≥ 1.5 × 10\^9/L, Hemoglobin (Hb) ≥ 8.5 g/L, Platelets (PLT) ≥ 75 × 10\^9/L.
• No history of severe arrhythmia or heart failure; no severe ventilation dysfunction or severe pulmonary infection; no acute or chronic renal failure with creatinine clearance \> 40 mL/min.
• Life expectancy of more than 3 months.

You may not qualify if:

• Major surgery within 28 days prior to enrollment.
• Presence of any unresolved toxicity of Grade ≥ 2 (according to Common Terminology Criteria for Adverse Events \[CTCAE\] v4.0) from prior anticancer therapy at the time of enrollment, with the exception of alopecia or Grade 2 anemia.
• Known hypersensitivity to any components or excipients of the study drugs.
• Presence of any active autoimmune disease or a history of autoimmune disease with an expected recurrence. Patients currently receiving immunosuppressants or systemic corticosteroids for immunosuppressive purposes.
• Presence of other concurrent malignancies.
• Presence of brain metastases or spinal cord compression.
• Presence of any severe and/or unstable pre-existing medical conditions, mental illness, or other conditions that could compromise patient safety, the ability to provide informed consent, or adherence to the study procedures.
• Pregnant or breastfeeding women.
• History of organ transplantation.
• Patients with proteinuria ≥ 1+ on urinalysis must undergo a 24-hour urine protein test. Patients with a 24-hour urine protein level ≥ 1g are excluded.
• Clinically significant corneal or retinal disease confirmed by ophthalmologic examination.
• Liver tumor burden exceeding 50%.
• Hypothyroidism or hyperthyroidism.

Sponsors & Collaborators

• Mao-Lin Yan: lead

Study Sites (1)

Affiliated Provincial Hospital of Fuzhou University

Fuzhou, Fujian, 350001, China

Location

MeSH Terms

Interventions

Immunotherapy

Intervention Hierarchy (Ancestors)

Immunomodulation; Biological Therapy; Therapeutics

Study Officials

• Maolin Lin, Doctor

  Department of Hepatobiliary and Pancreatic Surgery, Affiliated Provincial Hospital of Fuzhou University

  STUDY CHAIR

Central Study Contacts

Maolin Yan, Doctor

CONTACT

15960066307; yanmaolin74@163.com

Yu Zheng, Master

CONTACT

18605085811; zhengyufj@163.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: August 31, 2025
• First Posted: September 10, 2025
• Study Start: October 1, 2025
• Primary Completion (Estimated): October 1, 2029
• Study Completion (Estimated): October 31, 2029
• Last Updated: September 10, 2025

Record last verified: 2025-09

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)